INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2023

A review discusses current and emerging anti-obesity medications, including lipase inhibitors, GLP-1 agonists, leptin analogs, and MC4R agonists.

Obesity is a major public health concern associated with conditions like hypertension, type 2 diabetes, stroke, and cancer, affecting over a third of adults in the United States. While standard pharmacological agents such as lipase inhibitors and GLP-1 receptor agonists reduce weight gain by inhibiting fat absorption or stimulating satiety hormones, they are not effective for genetic disorders like Bardet-Biedl syndrome or POMC deficiency. Emerging therapies, including leptin analogs and MC4R agonists, target these genetic or hormonal causes to help regulate energy balance and appetite. The review discusses clinical trials, efficacy, FDA-approved indications, contraindications, and serious side effects of these medication classes.

Study type
Review
Who was studied
People with obesity, including genetic causes of obesity
What was measured
Efficacy, indications, contraindications, and side effects of anti-obesity medications

THE PAPER

Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges.

Brandfon S, Eylon A, Khanna D, Parmar MS. Cureus, 2023.

PubMed 37937009 ↗DOI 10.7759/cureus.46623 ↗

Diabetes & blood sugarCancerBlood pressureWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.